BAYRY News and Press, Bayer AG ADR From 04/08/23

2023-04-08 02:16:45 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-04-05 05:11:42 ET Bayer ( OTCPK:BAYRY ) ( OTCPK:BAYZF ) will invest ~€60M starting this year, in its corn seed production facility in Pochuiky, Ukraine. The German conglomerate noted that the investment is aimed at bolstering its Crop Science business in the countr...

2023-03-24 07:00:00 ET Summary With 2-5 year U.S. Treasury securities currently yielding 3-4%, it makes great sense to search for equities that offer us both a competitive dividend with possible upside potential. Add to that diversifying one's portfolio with top-rated equities in ...

2023-03-21 04:55:20 ET China's National Medical Products Administration (NMPA) approved Bayer ( OTCPK:BAYRY ) ( OTCPK:BAYZF ) and Orion Corporation's oral drug Nubeqa, in combination with docetaxel, to treat patients with metastatic hormone-sensitive prostate canc...

2023-03-10 04:37:22 ET Bayer ( OTCPK:BAYRY ) ( OTCPK:BAYZF ) said on Thursday that Asklepios BioPharmaceutical (AskBio) appointed Gustavo Pesquin as CEO, effective March 11. Pesquin will join gene therapy company AskBio — a wholly owned and independently o...

2023-03-09 06:56:19 ET Bayer ( OTCPK:BAYRY ) ( OTCPK:BAYZF ) intends to spend $1B on medicine research and development (R&D) in the U.S. in 2023, aimed at doubling revenue in the country by 2030, Reuters reported citing Sebastian Guth, president, Bayer's pharmace...

2023-03-08 00:56:48 ET Summary Our 3-step process focuses on wide-moat stocks (as per Morningstar’s rating). We are only interested in those targets that are attractively valued in historical comparison. We share the heat map of the most investable candidates that may b...

2023-03-07 09:15:00 ET Summary Inflation and (expected) actions by the Federal Reserve continue to dominate market movements. Markets have started the new year with very solid gains following expectations about a more dovish Federal Reserve and a solid earnings season. My divi...

Summary Bayer reported great results for fiscal 2022 with sales growing in the double digits, core EPS growing 22% and all three segments contributing to growth. And although Bayer is a little cautious for fiscal 2023 and expecting EBITDA and core EPS to decline, we can be optimistic ab...

The European Commission has granted marketing authorization in the European Union (EU) for Orion's ( OTCPK:ORINY ) darolutamide, an oral androgen receptor inhibitor (ARi), plus androgen deprivation therapy (ADT) in combination with docetaxel, for the treatment of patients with m...